Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis Kais Hussein, Angelika.

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox.

Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation Yasuhito Nannya, Akihito Shinohara, Motoshi.

Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients Stephanie Farnia,

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological.

Kidney and Bladder Outcomes in Children with Hemorrhagic Cystitis and BK Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation Benjamin.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M

Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome–Negative Myeloproliferative Neoplasms Olga Pozdnyakova, Robert.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation Yuan.

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia Lan-Ping Xu, Zheng-Li Xu, Xiao-Hui Zhang, Huan.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation Nicolaus Kröger, Victoria Panagiota, Anita.

Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis Nicolaus Kröger, Tatjana Zabelina,

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience

Characterizing Donor-Derived Cells in Nonhematopoietic Tissue

Sabina Kersting, Leo F. Verdonck

Biology of Blood and Marrow Transplantation

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Erratum to “Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic.

Evidence of a Graft-versus-Hodgkin Lymphoma Effect in the Setting of Extensive Bone Marrow Involvement Paolo Anderlini, MD Biology of Blood and Marrow.

Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Sclerodermatous Chronic Graft-versus-Host Disease: Clinical Report Hong Zhou,

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis Marie Robin,

Caroline F. Morrison, Donna M

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Cassius Torres-Pereira, Vaneuza Funke, Allan F. Giovanini, Celso A

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the.

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

B Cells and Transplantation: An Educational Resource

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturation.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

What is quality in a transplant program?

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Blood and Marrow Transplant Handbook

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Chimerism Patterns of Long-Term Stable Mixed Chimeras Posthematopoietic Stem Cell Transplantation in Patients with Nonmalignant Diseases: Follow-Up of.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation Francis Ayuk, Galina.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Presentation transcript:

Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis Kais Hussein, Angelika Stucki-Koch, Haefaa Alchalby, Ioanna Triviai, Nicolaus Kröger, Hans Kreipe Biology of Blood and Marrow Transplantation Volume 22, Issue 4, Pages 644-650 (April 2016) DOI: 10.1016/j.bbmt.2015.12.006 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Aberrant gene expression in PMF before and after transplantation. Mean and standard deviation are depicted by bars. Tx indicates treatment with ASCT. ∗P < .05,∗∗P < .01. Biology of Blood and Marrow Transplantation 2016 22, 644-650DOI: (10.1016/j.bbmt.2015.12.006) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Histological changes in PMF bone marrow before and after transplantation. (A) In this patient (case number 10; Supplementary Table 1), pre-ASCT bone marrow biopsy shows advanced stage PMF with aberrant megakaryocytic proliferation (arrows: enlarged and clustered cells; Giemsa, original magnifications ×200). (B) CD42b-staining highlights not only PMF megakaryocytes but also, as described earlier [21,33], the typical increase of interstitial proplatelet deposition (×400). (C) THBS1 is strongly expressed by aberrantly clustered megakaryocytes and is found in small particles, which represent megakaryocytic proplatelet depositions (×200). (D) Fibrosis with reticulin and collagen fibers and osteosclerosis represent the PMF cell–induced stromal changes in the bone marrow microenvironment (Gomorii silver, ×200). (E) After ASCT, the rebiopsy of the patient revealed hyperplastic bone marrow (hematoxylin and eosin, (×400). (F) CD42b reveals that megakaryocytes, which are donor-derived, show no aberrant clustering or increased proplatelet deposition. (G) Megakaryocytes express THBS1 but the number of megakaryocytes is almost normal. (H) In comparison to the PMF stage, after ASCT, the extracellular matrix is mainly normal and only focal areas with increased fibers indicate ongoing remodeling (Gomorii silver, ×200). Expressions of TIMPs are depicted in Supplementary Figure 1. Biology of Blood and Marrow Transplantation 2016 22, 644-650DOI: (10.1016/j.bbmt.2015.12.006) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions